SCHEMBL3537799

SCHEMBL3537799

O=C(O)CNC(=O)c1c(O)c(-c2nc3ccccc3s2)cc2nccnc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 3/20 0.61
HPGD P15428 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 7/20 0.42
EGLN1 Q9GZT9 3/20 0.42
TP53 P04637 2/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
EGLN2 Q96KS0 1/20 0.41
KDM4E B2RXH2 4/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535187 0.87 EGLN3 (0.46) EGLN3HPGDMAPTTP53MAPK1
SCHEMBL3521194 0.85 EGLN3 (0.62) EGLN3EGLN1FTO
SCHEMBL3766921 0.82 EGLN3 (0.69) EGLN3EGLN1EGLN2FTOKDM5B
SCHEMBL3522213 0.82 EGLN3 (0.83) EGLN3EGLN1EGLN2FTOKDM5B
SCHEMBL3522233 0.80 EGLN3 (0.61) EGLN3ALDH1A1EGLN1EGLN2RAB9A
SCHEMBL3528887 0.79 EGLN3 (0.62) EGLN3EGLN1TDP1EGLN2KMT2A
SCHEMBL3530935 0.79 EGLN3 (0.62) EGLN3MAPTEGLN1HSD17B10EGLN2
SCHEMBL3527877 0.78 EGLN3 (0.59) EGLN3EGLN1TSHRFTOKDM5B
SCHEMBL3763287 0.78 EGLN3 (0.70) EGLN3EGLN1EGLN2FTOKDM5B
SCHEMBL3517885 0.78 EGLN3 (0.67) EGLN3HPGDALDH1A1MAPTEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US claimed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP claimed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885HPGD 51/4885ALDH1A1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.